Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab vs Chemotherapy + PD-1/PD-L1 in First-line MSI-H/dMMR Gastric Cancer
NCT07127822Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Peking University. Started Dec 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07127822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127822.